A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Solid Cancer Clinical Trial

Official title:
A Single Arm, Open-label, Multicenter Phase 2 Study of Regorafenib in Participants Who Have Been Treated in a Previous Bayer-sponsored Regorafenib Study (Monotherapy or Combination Treatment) That Has Reached the Primary Completion Endpoint or the Main Data Analysis, or Has Been Stopped Prematurely.

Status Completed

Clinical Trial Summary

The purpose of this study is to enable participants, currently receiving regorafenib in a Bayer-sponsored clinical trial, to continue treatment after their respective study has been closed. Patients participating in this study will be observed to collect information on how safe the drugs are and how this treatment is tolerated.

Clinical Trial Description

The primary objectives of the study are a) to allow patients from Bayer-sponsored trials to continue regorafenib treatment after their respective study has been completed, and b) to further assess the safety of regorafenib. Secondary objective is the documentation of drug tolerability. ;

Study Design

Related Conditions & MeSH terms

Solid Cancer

Clinical Trial Details

NCT number	NCT03890731
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 2
Start date	April 2, 2019
Completion date	February 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03721679` - Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1	Phase 1/Phase 2
Recruiting	`NCT02884375` - Elderly CAncer Patient	N/A
Completed	`NCT00925743` - A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer	Phase 1
Recruiting	`NCT06161025` - A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT02376127` - Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
Completed	`NCT02959905` - Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)	Phase 1
Recruiting	`NCT04248348` - Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients
Recruiting	`NCT03311100` - Immunological Profile of Solid Tumors Sample	N/A